Company

Nionyx Bio

Nionyx Bio develops gene delivery technologies for gene therapies targeting kidney-related conditions.

About

Founded in 2025 and based in New York, Nionyx Bio develops gene therapy delivery systems focused on kidney-related conditions. Its technology includes purpose-built capsids and cassettes designed for targeted delivery. In October 2025, it raised USD 4.00 mn in seed funding led by 2048 Ventures, with participation from New York Ventures, White Mug Healthcare, AIN Ventures and Pathway Bioventures. The funding will support product development and expansion into Europe by the end of 2026.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in